CGTN: Why China is speeding up research on core technologies

BEIJING, Sept. 7, 2022 /PRNewswire/ — “Hello, everyone. I’m out of the module. I’m feeling good,” Chinese Taikonauts Chen Dong said when he kicked off his spacewalk last week.

Chen and fellow Shenzhou-14 crew member Liu Yang completed all six-hour-long extravehicular tasks on Friday (September 2), marking the fifth spacewalk outside China’s space station and the first out of the newly-launched Wentian lab module.

Since 2020, China has successfully carried out a series of flight mission, including the space station core module Tianhe, the Shenzhou-12 and Shenzhou-13 manned spacecraft, and the Tianzhou-2 and Tianzhou-3 cargo spacecraft, achieving remarkable progress in China’s space program.

Not only in aerospace, for the past decade, Chinese scientists are striving for breakthroughs in core technologies echoing President Xi Jinping’s call for resolute efforts to achieve breakthroughs in core technologies in key fields.

On Tuesday, Xi stressed improving a new system for mobilizing the resources nationwide to the core technologies research and development (R&D) while presiding over the 27th meeting of the Central Commission for Comprehensively Deepening Reform.

China should optimize the allocation of innovation resources based on the country’s strategic needs, strengthen the country’s strategic scientific and technological strength, greatly improve the systematic ability to tackle key scientific and technological problems, and cultivate competitive advantages and seize the strategic initiative in a number of important areas, Xi noted.

Mastering core technologies

“Core technologies cannot be purchased, or obtained by asking a favor from others or by begging,” Xi said during an inspection tour at Xi’an Institute of Optics and Precision Mechanics in 2015.

Since 2012, the Chinese president has highlighted the importance of scientific innovation and mastering core technology. Inspired by Xi, a large number of core technologies have made breakthroughs, making great strides toward the grand goal of China becoming a global leading power in science and technology.

The R&D in core technologies addresses major national needs. Cutting-edge solutions supported the implementation of major infrastructure projects such as the Hong Kong-Zhuhai-Macao Bridge and the Sichuan-Tibet Railway. The clean and efficient utilization of seabed oil and gas resources and coal, as well as the development of new-generation nuclear technologies, are vital to guaranteeing national energy security.

During COVID-19 epidemic, China has achieved a number of breakthroughs in vaccines, drugs and testing reagents. The number of approved new Class-I drugs in China has increased from five before 2012 to the current 79.

There are also a number of achievements with global influence. For instance, China has made the world’s first observation of the three-dimensional quantum Hall effect and the controlled folding of graphene with atomic-level precision, and developed the world’s first heterogeneous fusion brain-like computing chip “Tianji.”

Opening wider to the world

Last year, China announced to open its Five-hundred-meter Aperture Spherical Radio Telescope (FAST), the world’s largest filled-aperture and most sensitive radio telescope, to all scientists. Till June, the FAST has provided observation service to 27 scientific projects in 14 countries around the world.

The opening of FAST is one of the examples demonstrating that China is seriously expanding the circle of friends in science and technology.

Addressing a meeting conflating the general assemblies of the members of the Chinese Academy of Sciences and the Chinese Academy of Engineering (CAE), and the national congress of the China Association for Science and Technology (CAST) last year, Xi has called on Chinese sci-tech workers to promote openness, trust and cooperation with the international sci-tech community, actively participate in solving the major challenges facing mankind, and strive to promote the achievements of science and technology innovation to benefit more countries and people.

According to the Chinese Ministry of Science and Technology, China has built cooperative relations in the sci-tech field with 161 countries and regions, signed 115 intergovernmental agreements and joined more than 200 international organizations and multilateral mechanisms.

https://news.cgtn.com/news/2022-09-07/Why-China-is-speeding-up-research-on-core-technologies-1d8h2b5F89a/index.html

‫منظمة التعاون الرقمي تصدر العدد الأول من تقرير الازدهار الرقمي لتسليط الضوء على تنمية الاقتصاد الرقمي

الرياض، المملكة العربية السعودية7 سبتمبر / أيلول 2022 /PRNewswire/ — أصدرت منظمة التعاون الرقمي اليوم العدد الأول من تقرير الازدهار الرقمي، لتسليط الضوء على بعض القضايا الأكثر إلحاحاً لتنمية الاقتصاد الرقمي، ومبادرات وبرامج منظمة التعاون الرقمي التي تدعم الدول الأعضاء في المنظمة لتطوير اقتصادها الرقمي. 

DCO Digital Prosperity Report

ويهدف تقرير الازدهار الرقمي إلى تبادل أخر التحديثات حول أحدث أنشطة منظمة التعاون الرقمي، وهي منظمة دولية غير ربحية تركز على تمكين الازدهار الرقمي للجميع، من خلال مبادرات تسعى لتطوير السياسات، وإرساء أفضل الممارسات التي يمكن للدول الأعضاء تطبيقها على برامجها الخاصة، بهدف إنشاء اقتصادات رقمية عادلة ومستدامة تمكن مواطنيها .

ويتضمن العدد الأول من التقرير مقدمةً بقلم رئيس المنتدى الاقتصادي العالمي، السيد بورجه بريندي، حيث تحدث عن مبادرة الاستثمار الأجنبي المباشر الرقمي التي أطلقها المنتدى في مدينة دافوس بسويسرا مع منظمة التعاون الرقمي لدعم الاستثمار الأجنبي المباشر في الاقتصاد الرقمي، وزيادة الانتعاش العالمي في الاستثمار الأجنبي المباشر بعد جائحة كوفيد-19 . كما يشمل العدد مقابلةً حصريةً مع معالي السيدة باولا إنغابير، وزيرة تكنولوجيا المعلومات والاتصالات والابتكار في رواندا، تتناول  سياسة الاقتصادي الرقمي لبلدها، ودور تكنولوجيا المعلومات والاتصالات في التنمية، وكيف تسهم عضوية منظمة التعاون الرقمي في تعزيز الأهداف الاستراتيجية لرواندا في المجال الرقمي .

ويناقش هذا العدد الفجوة بين الجنسين في قطاع الشركات الناشئة، وكيف يمكن لمعالجة الفجوة أن تسهم في تمكين المرأة من الحصول على فرص أفضل، فضلاً عن دراسة التحديات التي تواجه التشريعات الفعالة لحماية بيانات المستخدم النهائي، كما يتضمن تقريراً عن المبادرة الجديدة للاستثمار الأجنبي المباشر الرقمي التي أطلقت مؤخراً من منظمة التعاون الرقمي والمنتدى الاقتصادي العالمي .

ويتضمن التقرير نظرةً ثاقبةً على أنشطة منظمة التعاون الرقمي القادمة، بما في ذلك مبادرة سلسلة النقاشات العالمية DCO Round Tables ، ومبادرة STRIDE لدعم الشركات الناشئة الرقمية، ومؤشر نضج الاقتصاد الرقمي ( DEMI ) ، ومركز التميز لتدفقات البيانات التابع لمنظمة التعاون الرقمي .

وبمناسبة إطلاق التقرير، ذكرت الأستاذة ديمة اليحيى، الأمين العام لمنظمة التعاون الرقمي : “ تأسست منظمة التعاون الرقمي لتمكين الازدهار الرقمي للجميع، ودعم دولنا الأعضاء من خلال تمكين تبادل المعرفة والتعاون في تطوير أفضل الممارسات والسياسات والاستراتيجيات لتسريع تحولها الرقمي، وبالتالي دعم تطوير اقتصاد وطني رقمي وشامل ومزدهر ومستدام ويعد تقرير الازدهار الرقمي جزءاً مهماً من هذا الالتزام بتبادل المعرفة، والذي يسلط الضوء على أنشطة منظمة التعاون الرقمي ودولنا الأعضاء، ويقدم التقرير تعليقات الخبراء من المؤثرين الرئيسيين والبارزين، ويلفت الانتباه إلى قضايا مهمة مثل معالجة عدم المساواة بين الجنسين في الاقتصاد الرقمي وسد الفجوة الرقمية بين الجنسين، وتحديات حماية بيانات المستخدم النهائي .” وأضافت اليحيى : “يعد التقرير الأول مرجعاً مهماً للمهتمين في الاطلاع على آخر التطورات في الاقتصاد الرقمي العالمي، ولا سيما في الدول الأعضاء في منظمة التعاون الرقمي “.

وتجدر الإشارة إلى أن تقرير منظمة التعاون الرقمي للازدهار الرقمي متاح حالياً Digital Prosperity Report (dcoinsights.com)

The Digital Cooperation Organization (DCO) LogoPhoto – https://mma.prnewswire.com/media/1893527/DCO.jpg
Logo – https://mma.prnewswire.com/media/1867632/DCO_Logo.jpg

Liechtenstein NationalMuseum opens CUSP – Rashid Al Khalifa

VADUZ, Liechtenstein, Sept. 7, 2022 /PRNewswire/ — This Wednesday, September 7th 2022, the Liechtenstein NationalMuseum opens CUSP, a mini retrospective presenting a selection of works by Bahraini artist Rashid Al Khalifa, from atmospheric landscape paintings that mark the beginning of his artistic career in the 1970s, to his latest robust aluminium and steel installations. The exhibition will remain open until October 16th 2022.

Despite the diversity of Rashid Al Khalifa’s oeuvre in terms of style and medium, there is an undercurrent that flows through decades of creative work, driven by Rashid’s desire to develop and evolve. In many respects, the stylistic transitions that define certain periods, reflect the changing landscape of Bahrain and the passages of Rashid’s life.

Rashid Al Khalifa’s style of work has undergone a significant evolution over the years with the surroundings that have long inspired him but if we are to truly understand the essence of his oeuvre, we find that he has undergone a very conscious journey. Rashid has always aimed to express the fundamentality of life, through the contrasts he has regularly observed in his immediate environment, as well as the colours and light reflected in a land that he treasures.

“I am grateful to be exhibiting in Vaduz for the second time this year, and to have the opportunity to present this selection of works that define certain periods of my artistic career. I often draw on aspects of my heritage, culture and surroundings and I am so pleased to share my most personal work in a country with such a rich culture and amongst a people with whom I was previously so warmly received.” said the artist Rashid Al Khalifa.

Born in 1952, Rashid Al Khalifa studied Art and Design at Hastings College of Art and Design, Sussex, England. Beginning his artistic career focusing on landscape painting, his oeuvre is by and large defined by changes in style, which parallel changes in his life and environment. Figurative, ephemeral oil paintings from the ’80s, transformed into abstract forms in the ’90s, leading to Rashid’s experimentation with other materials and surfaces, such as his characteristic ‘convex canvas’. In the 2000s, Rashid began to abstract his work to a greater extent, removing details and adapting various textures on the surface. Aluminium became the focus of his work from 2010 onwards, first by employing glossy lacquer paint on its smooth façade, and then focusing on enamel, which lead to a much more minimalistic approach to his work. First by employing glossy lacquer paint on its smooth façade, and then focusing on enamel, which lead to a much more minimalistic approach to his work.

Rashid Al Khalifa has exhibited in numerous international exhibitions, art fairs and biennales, including: Rashid Al Khalifa, Opera Gallery, Dubai, UAE (2021); Tesselate, Mario Mauroner Gallery, Vienna, Austria (2021); Transverse Wave, me Collectors Room, Berlin, Germany (2019), Penumbra, Saatchi Gallery, London (2018); Moscow Biennale, Moscow, Russia (2019); Contemporary Istanbul, Istanbul, Turkey (2019, 2021); SCOPE, Miami Beach, Miami, USA (2021); to name a few.

A prominent artist and respected collector, HE Shaikh Rashid bin Khalifa Al Khalifa currently serves as Chairman of the newly established Arts Council in Bahrain. He has long been regarded a patron and ardent supporter of the arts, and in 2020, established the RAK Art Foundation with the intention of providing a platform as well as offering opportunities to emerging artists and creatives, as well as making his collection of international contemporary art (on display throughout the grounds of the Foundation), accessible the public.

“I am delighted and honoured to have had the opportunity to exhibit the fascinating work of HE Shaikh Rashid bin Khalifa Al Khalifa. It is through this exhibition that we are able to gain insight into the rich and multi-layered history and culture of Bahrain, which in many ways, mirrors our own. I hope that through this exhibition, we will grow to better understand one another and learn from each other. We are so grateful to His Excellency Shaikh Rashid Al Khalifa for this opportunity.” Expressed Rainer Vollkommer, Director of the Liechtenstein NationalMuseum.

Dating back to 1438, the three buildings that now house the Liechtenstein National Museum consist of 42 exhibit rooms which display the museum’s permanent collection and special exhibitions. Encompassing archaeology, history & religion, daily-life in Liechtenstein and the natural environment, the Liechtenstein National Museum aims to present the rich and diverse history of the principality. Visitors gain insight into the local population, the Princely House, daily life and the history of Liechtenstein. The Museum organizes public and private guided tours, activities for children and families and educational programs.

The exhibition will remain open until October 16th 2022.

Liechtenstein NationalMuseum, Prof. Dr. Rainer Vollkommer, Director, Städtle 43, Postfach 1216, 9490 Vaduz, Principality Liechtenstein
P +423 239 68 20, info@landesmuseum.liwww.landesmuseum.li

rashidalkhalifa.com | rakartfoundation.com
For Press enquiries, please contact: Ms. Svetlana Prodanova Media Consultant, RAK Art Foundation svetlana@intelhot.com.bh | +973 36609983

– Picture is available at AP Images (http://www.apimages.com) –

Liechtenstein NationalMuseum, Stadtle 43,
FL-9490 Vaduz
September 8th-October 16th, 2022

Payment Fraud Intelligence Expands The Recorded Future Intelligence Cloud

Real-Time Dark Web Intelligence Empowers Financial Institutions, Card Issuers, and E-commerce Providers to Prevent Payment Fraud

BOSTON, Sept. 7, 2022 /PRNewswire/ — Recorded Future, the world’s largest intelligence company, today announced the expansion of its Intelligence Cloud with Payment Fraud Intelligence, a single source of truth for identifying, mitigating, and preventing payment fraud. Payment Fraud Intelligence enables those focused on payment fraud, including financial institutions, card issuers, and e-commerce providers to disrupt the entire payment fraud lifecycle by helping to detect e-skimmer infrastructurecompromised cards, and crypto wallets associated with malicious activity.

Payment fraud is a multi-billion dollar industry impacting merchants, cardholders, and financial institutions, and will result in over $400 billion in losses globally over the next decade. Historically, the industry has taken a reactive approach, waiting until fraudulent purchases take place, then attempting to limit losses, resulting in further reputational damages and financial losses. Recorded Future has unparalleled visibility into the complete payment fraud infrastructure, enabling clients to disrupt criminal activity by proactively detecting payment data being sold on the dark web, finding e-commerce sites infected with e-skimmers, and mapping thousands of the tester merchants used to validate cards before they’re used fraudulently.

Recorded Future’s Payment Fraud Intelligence enables payment fraud teams to proactively:

  • Pinpoint compromised common points of purchase (CPPs)
  • Enhance risk-exposure models and lower fraud potential
  • Improve average fraud rate metrics across an entire card portfolio
  • Detect attacker infrastructure being used to skim payment card data

With Recorded Future Payment Fraud Intelligence, the Card Fraud Prevention team at Swedbank is automatically alerted when its cards have been compromised and posted for sale on the dark web, enabling them to preemptively block and replace cards before fraud can occur.

“Recorded Future integrates with fraud detection systems to improve efficacy of detection algorithms and proactively scans the dark web to find compromised cards and reveal attacker infrastructure to identify active infections and full exposure periods. Now, financial institutions can develop and implement effective mitigation strategies to counter the effect of payment card compromises and subsequent fraud attacks before attacks can occur.” – Andrei Barysevich, Vice President, Fraud Solutions, Recorded Future

Learn more about Recorded Future Payment Fraud Intelligence: https://www.recordedfuture.com/platform/payment-fraud-intelligence

Request a demo of Recorded Future Payment Fraud Intelligence: https://go.recordedfuture.com/demo

About Recorded Future

Recorded Future is the world’s largest intelligence company. Recorded Future’s Intelligence Cloud provides complete coverage across adversaries, infrastructure, and targets. By combining persistent and pervasive automated data collection and analytics with human analysis, Recorded Future provides real-time visibility into the digital landscape and empowers clients to take proactive action to disrupt adversaries and keep their people, systems, and infrastructure safe. Headquartered in Boston with offices and employees around the world, Recorded Future works with over 1,500 businesses and government organizations across more than 64 countries. Learn more at recordedfuture.com.

Logo – https://mma.prnewswire.com/media/705622/Recorded_Future_Logo.jpg

Miami International Holdings Reports August 2022 Trading Results; MIAX Options, MIAX Pearl Equities and SPIKES Futures Set Year-to-Date Volume Records

PRINCETON, N.J., Sept. 7, 2022 /PRNewswire/ — Miami International Holdings, Inc. (MIH) today reported August 2022 trading results for its U.S. exchange subsidiaries – MIAX®, MIAX Pearl® and MIAX Emerald® (together, the MIAX Exchange Group™), and Minneapolis Grain Exchange (MGEX™).

August 2022 Trading Volume Highlights

  • Total U.S. multi-listed options market share for the MIAX Exchange Group reached 12.79%, representing a 16.0% year-over-year (YoY) decrease. A total of 108.1 million multi-listed options contracts were executed on the MIAX Exchange Group, representing a 6.8% decrease YoY and an average daily volume (ADV) of 4,699,129 contracts. Total year-to-date (YTD) volume reached 863.8 million contracts, a decrease of 1.7% from the same period in 2021.
  • MIAX Options reported record YTD volume of 360.6 million contracts, up 6.0% from the same period in 2021, with volume reaching 47.0 million contracts in August 2022, a 0.3% YoY decrease. MIAX Emerald reported YTD volume of 217.2 million contracts, an 8.1% decrease from the same period in 2021, with volume totaling 25.4 million contracts in August 2022, a 39.2% YoY decrease. MIAX Pearl reported YTD volume of 286.0 million contracts, a 5.2% decrease from the same period in 2021, with volume totaling 35.7 million contracts in August 2022, a 31.9% YoY increase.
  • In U.S. equities, MIAX Pearl Equities™ reported volume of 2.4 billion shares in August 2022, representing a 210.2% increase YoY and a market share of 0.98%. Total YTD volume reached a record 19.6 billion shares, a 316.9% increase from the same period in 2021.
  • In U.S. futures, MGEX, a Designated Contract Market (DCM) and Derivatives Clearing Organization (DCO), reported trading volume of 376,441 contracts in August 2022, a 4.6% decrease YoY. Total YTD volume reached 2,400,396 contracts, a decrease of 3.0% from the same period in 2021.
  • SPIKES® Futures volume totaled 160,628 contracts in August 2022, representing an 87.0% increase YoY and an average daily volume of 6,984 contracts. Total YTD volume reached a record of 538,417 contracts, a 314.8% increase YoY.

Additional MIAX Exchange Group and MGEX volume details are included in the following tables.

Multi-Listed Options Trading Volume for

 MIAX Exchange Group, Current Month

Year-to-Date Comparison
Multi-Listed Options
Contracts
Aug-22 Aug-21 % Chg Jul-22 % Chg Aug-22 Aug-21 % Chg
Trading Days 23 22 20 167 167
U.S. Equity Options Industry 845,104,433 761,891,872 10.9 % 685,359,630 23.3 % 6,285,805,288 6,132,683,722 2.5 %
MIAX Exchange Group 108,079,977 116,013,478 -6.8 % 92,981,667 16.2 % 863,818,014 878,372,405 -1.7 %
MIAX Options 46,972,524 47,123,249 -0.3 % 40,410,802 16.2 % 360,617,154 340,247,261 6.0 %
MIAX Pearl 35,696,808 27,068,706 31.9 % 31,905,134 11.9 % 286,036,788 301,731,215 -5.2 %
MIAX Emerald 25,410,645 41,821,523 -39.2 % 20,665,731 23.0 % 217,164,072 236,393,929 -8.1 %
Multi-Listed Options ADV Aug-22 Aug-21 % Chg Jul-22 % Chg Aug-22 Aug-21 % Chg
U.S. Equity Options Industry 36,743,671 34,631,449 6.1 % 34,267,982 7.2 % 37,639,553 36,722,657 2.5 %
MIAX Exchange Group 4,699,129 5,273,340 -10.9 % 4,649,083 1.1 % 5,172,563 5,259,715 -1.7 %
MIAX Options 2,042,284 2,141,966 -4.7 % 2,020,540 1.1 % 2,159,384 2,037,409 6.0 %
MIAX Pearl 1,552,035 1,230,396 26.1 % 1,595,257 -2.7 % 1,712,795 1,806,774 -5.2 %
MIAX Emerald 1,104,811 1,900,978 -41.9 % 1,033,287 6.9 % 1,300,384 1,415,533 -8.1 %
Multi-Listed Options Market Share for

MIAX Exchange Group, Current Month

Year-to-Date Comparison
Multi-Listed Options Market
Share
Aug-22 Aug-21 % Chg Jul-22 % Chg Aug-22 Aug-21 % Chg
MIAX Exchange Group 12.79 % 15.23 % -16.0 % 13.57 % -5.7 % 13.74 % 14.32 % -4.1 %
MIAX Options 5.56 % 6.19 % -10.1 % 5.90 % -5.7 % 5.74 % 5.55 % 3.4 %
MIAX Pearl 4.22 % 3.55 % 18.9 % 4.66 % -9.3 % 4.55 % 4.92 % -7.5 %
MIAX Emerald 3.01 % 5.49 % -45.2 % 3.02 % -0.3 % 3.45 % 3.85 % -10.4 %

 

Equities Trading Volume for

MIAX Pearl Equities, Current Month

Year-to-Date Comparison
Equities Shares (millions) Aug-22 Aug-21 % Chg Jul-22 % Chg Aug-22 Aug-21 % Chg
Trading Days 23 22 20 167 167
U.S. Equities Industry 243,296 198,029 22.9 % 214,812 13.3 % 2,036,953 1,959,231 4.0 %
Miax Pearl Volume 2,396 773 210.2 % 1,962 22.1 % 19,624 4,708 316.9 %
MIAX Pearl ADV 104 35 196.7 % 98 6.2 % 118 28 316.9 %
MIAX Pearl Market Share 0.98 % 0.39 % 152.5 % 0.91 % 7.8 % 0.96 % 0.24 % 301.0 %

 

Futures & Options Trading Volume for

MGEX, Current Month

Year-to-Date Comparison
Futures & Options Contracts Aug-22 Aug-21 % Chg Jul-22 % Chg Aug-22 Aug-21 % Chg
Trading Days 23 22 20 167 167
MGEX Futures Volume 376,441 394,528 -4.6 % 236,941 58.9 % 2,400,396 2,475,882 -3.0 %
MGEX ADV 16,367 17,933 -8.7 % 11,847 38.2 % 14,374 14,826 -3.0 %

 

About MIAX
MIAX’s parent holding company, Miami International Holdings, Inc., owns Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), Minneapolis Grain Exchange, LLC (MGEX™), and The Bermuda Stock Exchange (BSX™).

MIAX, MIAX Pearl and MIAX Emerald are national securities exchanges registered with the Securities and Exchange Commission (SEC) that are enabled by our in-house built, proprietary technology. MIAX offers trading of options on all three exchanges as well as cash equities through MIAX Pearl Equities™. The MIAX trading platform was built to meet the high-performance quoting demands of the U.S. options trading industry and is differentiated by throughput, latency, reliability and wire-order determinism. MIAX also serves as the exclusive exchange venue for cash-settled options on the SPIKES® Volatility Index (Ticker: SPIKE), a measure of the expected 30-day volatility in the SPDR® S&P 500® ETF (SPY).

MGEX is a registered exchange with the Commodity Futures Trading Commission (CFTC) and serves as the exclusive market for a variety of products including Hard Red Spring Wheat and SPIKES Futures. MGEX is a Designated Contract Market (DCM) and Derivatives Clearing Organization (DCO) under the CFTC, providing DCM, DCO and cash market services in an array of asset classes.

BSX is a fully electronic, vertically integrated international securities market headquartered in Bermuda and organized in 1971. BSX specializes in the listing and trading of capital market instruments such as equities, debt issues, funds, hedge funds, derivative warrants, and insurance linked securities.

MIAX’s executive offices and National Operations Center are located in Princeton, N.J., with additional offices located in Miami, FL, Minneapolis, MN, and Hamilton, Bermuda.

To learn more about MIAX visit www.MIAXOptions.com.

To learn more about MGEX visit www.mgex.com.

To learn more about BSX visit www.bsx.com.

Disclaimer and Cautionary Note Regarding Forward-Looking Statements

The press release shall not constitute an offer to sell or a solicitation of an offer to purchase any securities of Miami International Holdings, Inc. (together with its subsidiaries, the Company), and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer; solicitation or sale would be unlawful. This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

All third-party trademarks (including logos and icons) referenced by the Company remain the property of their respective owners. Unless specifically identified as such, the Company’s use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between the owners of these trademarks and the Company. Any references by the Company to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

Media Contact:
Andy Nybo, SVP, Chief Communications Officer
(609) 955-2091
anybo@miami-holdings.com

Logo – https://mma.prnewswire.com/media/1396492/MIAX_Logo.jpg

 

Zenas BioPharma nomme Simon Lowry, M.D. au poste de directeur médical

WALTHAM, Mass. et SHANGHAI, Chine, 07 sept. 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de thérapies immunitaires pour les patients dans le besoin à travers le monde, a annoncé aujourd’hui la nomination de Simon Lowry, M.D., au poste de directeur médical de la société. Le Dr Lowry apporte plus de 20 ans d’expertise clinique dans la conception et l’exécution de programmes cliniques de stade précoce à avancé à Zenas, où il dirigera les fonctions cliniques, médicales et de pharmacovigilance de la société au niveau international.

« Nous sommes ravis d’accueillir le Dr Lowry au sein de Zenas à ce moment crucial pour la société, alors que nous commençons deux essais d’enregistrement de phase trois pour notre principal produit candidat, l’obexelimab, au quatrième trimestre de cette année, et que nous entamons les premiers essais cliniques sur l’homme pour plusieurs programmes en cours », a déclaré Hua Mu, M.D., Ph. D, président-directeur général de Zenas. « Le leadership éprouvé du Dr Lowry, sa vaste expérience du développement clinique et sa grande expérience en matière d’essais cliniques à l’échelle mondiale renforceront davantage notre capacité à mener à bien notre mission, qui consiste à transformer la vie des patients dont les besoins médicaux ne sont pas satisfaits, en leur proposant les meilleurs traitements immunitaires de leur catégorie. »

Le Dr Simon Lowry a ajouté : « De nombreux patients atteints de maladies rares et auto-immunes ont besoin d’options thérapeutiques nouvelles et efficaces. L’équipe de Zenas, très expérimentée et talentueuse, a considérablement développé son portefeuille en très peu de temps, et je suis impatient de diriger l’avancement continu des programmes cliniques de Zenas jusqu’à la commercialisation, tout en renforçant le portefeuille de programmes innovants de la société. »

Le Dr Lowry est un médecin possédant 20 ans d’expérience dans des sociétés pharmaceutiques et biotechnologiques importantes et émergentes, où il a dirigé des programmes de développement fructueux, des équipes d’affaires cliniques et médicales, et interagi avec des organismes de réglementation dans plusieurs domaines de la médecine, y compris la rhumatologie, l’immunologie et l’ophtalmologie. Avant de rejoindre Zenas, le Dr Lowry était directeur médical chez Kinevant Science, une société biopharmaceutique au stade clinique, spécialisée dans le traitement des maladies inflammatoires et auto-immunes rares. Le Dr Lowry était auparavant responsable de la R&D en immunologie chez Roivant Sciences, où il dirigeait tous les actifs de l’immunologie en phase de développement clinique, et était un membre clé de l’équipe de direction. Il a également occupé le poste de directeur médical chez Sun Pharma North America, où il était responsable de quatre domaines thérapeutiques de marque (immunologie et dermatologie, ophtalmologie, neurologie et oncologie), et a dirigé tous les aspects du développement et des fonctions médicales (y compris le développement clinique, les informations médicales, la médecine de terrain, La recherche sur l’économie et les résultats de la santé (HEOR), les publications/communications médicales et les opérations). Au début de sa carrière, il a travaillé chez Novartis, où il a occupé le poste de vice-président, directeur de franchise des affaires médicales mondiales, immunologie et dermatologie, et chez Pfizer, où il a occupé des postes à responsabilité croissante, notamment celui de vice-président du groupe des affaires médicales en oncologie.

Avant sa carrière dans le secteur pharmaceutique/biotechnologique, le Dr Lowry a pratiqué la médecine interne dans diverses institutions au Royaume-Uni et en Australie. Il a obtenu son BA au Trinity Hall, de l’université de Cambridge, au Royaume-Uni et son diplôme médical MB BChir à la Cambridge University School of Clinical Medicine.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients dans le monde entier. Avec un développement clinique et des activités aux États-Unis et en Chine, Zenas fait rapidement progresser un important programme de traitements innovants qui continue de s’accroître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes confrontées à des maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le site www.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Contact auprès des investisseurs et des médias :
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer

WALTHAM, Mass. and SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer. Dr. Lowry brings over 20 years of broad clinical expertise in the design and execution of early to late-stage clinical programs to Zenas, where he will lead the company’s global clinical, medical affairs, and pharmacovigilance functions.

“We are delighted to welcome Dr. Lowry to Zenas at this pivotal time for the company as we commence two phase three registration trials for our lead product candidate, obexelimab, in the fourth quarter of this year and initiate first-in-human clinical trials for multiple pipeline programs,” said Hua Mu, M.D., Ph. D, Chief Executive Officer at Zenas. “Dr. Lowry’s proven leadership, broad clinical development background, and extensive global clinical trial experience will further strengthen our ability to execute on our mission to transform the lives of patients with unmet medical needs by bringing best-in-class immune-based therapies to patients.”

Dr. Simon Lowry added, “There are many patients with autoimmune and rare diseases in need of effective new treatment options. The deeply experienced and talented Zenas team has made impressive progress advancing the company’s pipeline in a very short period of time, and I look forward to leading the ongoing advancement of Zenas’ clinical programs through commercialization while further expanding the company’s pipeline of innovative programs.”

Dr. Lowry is a medical doctor with 20 years of experience at large and emerging pharmaceutical and biotechnology companies directing successful development programs, leading clinical and medical affairs teams, and interacting with regulatory agencies across multiple areas of medicine, including rheumatology, immunology, and ophthalmology. Prior to joining Zenas, Dr. Lowry was Chief Medical Officer at Kinevant Science, a clinical-stage biopharmaceutical company focused on treating rare inflammatory and autoimmune diseases. Dr. Lowry was previously Head of Immunology R&D at Roivant Sciences, leading all development stage immunology assets into clinical development, and served as a key member of the leadership team. He also served as Chief Medical Officer at Sun Pharma North America, where he was responsible for four branded therapeutic areas (Immunology & Dermatology, Ophthalmology, Neurology and Oncology), and led all aspects of development and medical functions (including clinical development, medical information, field medical, HEOR, publications / medical communications, and operations). Early in his career, he worked at Novartis, where he served as Vice President, Global Medical Affairs Franchise Head, Immunology & Dermatology, and Pfizer, where he served in roles of increasing responsibility, including as Vice President, Oncology Medical Affairs Group Leader.

Prior to his pharmaceutical/ biotechnology career, Dr. Lowry practiced internal medicine at various institutions in the UK and Australia. He received his BA from Trinity Hall, Cambridge University, UK and his MB BChir medical degree from Cambridge University School of Clinical Medicine.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations in the US and China, Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Zenas BioPharma Nomeia Simon Lowry, M.D. para Diretor Médico

WALTHAM, Mass. e SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias imunológicas, anunciou hoje a nomeação de Simon Lowry, MD para seu Conselho Diretor. O Dr. Lowry tem mais de 20 anos de ampla experiência clínica na concepção e execução de programas clínicos de estágio inicial a final na Zenas, onde ele passará a liderar as funções globais de clínica, assuntos médicos e farmacovigilância da empresa.

“Estamos muito contentes em receber o Dr. Lowry na Zenas neste momento crucial para a empresa, quando damos início a dois testes de registro de fase três do nosso principal candidato a produto, obexelimabe, no quarto trimestre deste ano, e aos primeiros testes clínicos em humanos de vários programas de pipeline”, disse Hua Mu, M.D., Ph.D., Diretor Executivo da Zenas. “A liderança comprovada do Dr. Lowry, seu amplo histórico de desenvolvimento clínico e extensa experiência com ensaios clínicos globais irão fortalecer ainda mais nossa capacidade de executar nossa missão de transformar a vida dos pacientes com necessidades médicas não atendidas, com a oferta das melhores terapias imunológicas aos pacientes.”

O Dr. Simon Lowry acrescentou: “Há muitos pacientes com doenças autoimunes e raras que precisam de novas opções de tratamento eficazes. A equipe profundamente experiente e talentosa da Zenas fez um progresso impressionante ao avançar no pipeline da empresa em um período muito curto de tempo, e estou pronto para liderar o avanço contínuo dos programas clínicos da Zenas com a sua comercialização e maior expansão do pipeline de programas inovadores da empresa.”

O Dr. Lowry tem 20 anos de experiência com grandes empresas farmacêuticas e de biotecnologia emergentes, tendo dirigido programas de desenvolvimento bem-sucedidos, liderado equipes de assuntos clínicos e médicos, e interagido com agências reguladoras em várias áreas da medicina, incluindo reumatologia, imunologia e oftalmologia. Antes de ingressar na Zenas, o Dr. Lowry foi Diretor Médico da Kinevant Science, uma empresa biofarmacêutica de estágio clínico focada no tratamento de doenças inflamatórias e autoimunes raras. Anteriormente, o Dr. Lowry foi Chefe de Pesquisa e Desenvolvimento em Imunologia da Roivant Sciences, liderando todos os ativos de imunologia em estágio de desenvolvimento para o desenvolvimento clínico, e serviu como um membro-chave da equipe de liderança. Ele também atuou como Diretor Médico na Sun Pharma North America, onde foi responsável por quatro áreas terapêuticas de marca (Imunologia e Dermatologia, Oftalmologia, Neurologia e Oncologia) e liderou todos os aspectos do desenvolvimento e funções médicas (incluindo desenvolvimento clínico, informações médicas, medicina de campo, HEOR, publicações/comunicações médicas e operações). No início da sua carreira, ele trabalhou na Novartis, onde atuou como Vice-Presidente, Chefe de Franquia de Assuntos Médicos Globais, Imunologia e Dermatologia, e na Pfizer, onde atuou em funções de responsabilidade crescente, incluindo como Vice-Presidente, Líder do Grupo de Assuntos Médicos de Oncologia.

Antes da sua carreira farmacêutica/biotecnológica, o Dr. Lowry exerceu medicina interna em várias instituições no Reino Unido e na Austrália. Ele é formado em Medicina pela Trinity Hall, Cambridge University e pela Cambridge University School of Clinical Medicine no Reino Unido.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial comprometida em se tornar líder global no desenvolvimento e comercialização de terapias imunológicas para pacientes em todo o mundo. Com desenvolvimento clínico e operações nos EUA e na China, a Zenas está avançando rapidamente um vasto pipeline de terapêuticas inovadoras que continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com